Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07347782

AI-Based Speech Intelligibility Assessment: Efficacy & Reliability

compare the auditory-perceptual assessment conducted by speech-language pathologists using the U-TAP with the assessment performed via the AI solution (Blings) program in patients with speech disorders, and to evaluate the efficacy and reliability of these two methods for speech intelligibility assessment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 years or older.
  • Patients with neurologic disorders, including amyotrophic lateral sclerosis, poliomyelitis, cerebellar disorders, cerebellar lesions, and stroke.
  • Patients presenting with concomitant speech disorders, such as dysarthria, motor speech disorders, and voice disorders.

Exclusion criteria

  • Subjects with a score of less than 16 points on the Korean Mini-Mental State Examination (K-MMSE).
  • Subjects with visual, perceptual, or auditory impairments that prevent them from following the examiner's instructions.
  • Subjects judged by the researcher as unsuitable for participation in this clinical study due to other reasons.

Treatment and study plan

Primary outcomes

  1. Word-level consonant accuracy (%) derived from speech samples obtained during the U-TAP assessment

    Time frame: Visit 1 (Baseline)

    The agreement between consonant accuracy analyzed by the AI-based speech disorder analysis program (Blings) and the evaluations conducted independently by two certified speech-language pathologists (Rater 1 and Rater 2). Consonant accuracy is calculated at the word level and expressed as a percentage score ranging from 0% to 100%. The mean value of consonant accuracy scores from Rater 1 and Rater 2 is used as the reference human evaluation.

Secondary outcomes

  1. Test-retest reliability of word-level consonant accuracy (%) calculated by Blings

    Time frame: Visit 1 and Visit 2 (7 ± 5 days interval)

    The consistency of consonant accuracy scores generated by Blings from the same participant across two visits. Comparison of Blings-derived consonant accuracy scores (%) between Visit 1 and Visit 2. Scores range from 0% to 100%.

  2. Inter-rater agreement of word-level consonant accuracy (%) among Blings, Rater 1, and Rater 2

    Time frame: Visit 1 and Visit 2 (7 ± 5 days interval)

    Agreement in consonant accuracy evaluations between the AI-based analysis and human raters. Pairwise comparisons: Rater 1 vs. Rater 2, Blings vs. Rater 1, Blings vs. Rater 2. Scores expressed as percentages (0-100%)

  3. Time required to complete speech analysis (seconds)

    Time frame: Visit 1 and Visit 2 (7 ± 5 days interval)

    Comparison of analysis time between the AI-based system (Blings) and human raters. Total analysis time measured in seconds for: Rater 1, Rater 2, Blings

Study contacts

Contact information is provided by the study sponsor or research team.

Jisoo Baik

CONTACT

[email protected]

082+055-360-4159

Sponsors and collaborators

Lead sponsor

Pusan National University Yangsan Hospital

Other

Registry information

Official study title

Clinical Study on the Efficacy and Reliability of Speech Intelligibility Assessment for Post-stroke Patients Using an AI Solution

Acronym: AI Solution

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 16, 2026
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.